Miller S, Maio G, Zhang X, Badillo Soto F, Zhu J, Ramirez S, et al. A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions. Mol Cell Proteomics. 2022;21:100268 pubmed publisher

Röck R, Mayrhofer J, Torres Quesada O, Enzler F, Raffeiner A, Raffeiner P, et al. BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Sci Adv. 2019;5:eaav8463 pubmed publisher

Ruicci K, Pinto N, Khan M, Yoo J, Fung K, Macneil D, et al. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. Oral Oncol. 2018;84:95-103 pubmed publisher

Takashina M, Inoue S, Tomihara K, Tomita K, Hattori K, Zhao Q, et al. Different effect of resveratrol to induction of apoptosis depending on the type of human cancer cells. Int J Oncol. 2017;50:787-797 pubmed publisher

Lee G, Won H, Lee Y, Choi J, Oh T, Jang J, et al. Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1α Activation. Sci Rep. 2016;6:18928 pubmed publisher

Antic I, Biancucci M, Zhu Y, GIUS D, Satchell K. Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nat Commun. 2015;6:7396 pubmed publisher

Rodriguez Viciana P, Warne P, Khwaja A, Marte B, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89:457-67 pubmed